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In the last decades, tremendous advancement in dissecting themechanisms of pathogenicity ofNeisseriameningitidis at amolecular
level has been achieved, exploiting converging approaches of different disciplines, ranging from pathology to microbiology,
immunology, and omics sciences (such as genomics and proteomics). Here, we review the molecular biology of the infectious
agent and, in particular, its interactions with the immune system, focusing on both the innate and the adaptive responses.
Meningococci exploit different mechanisms and complex machineries in order to subvert the immune system and to avoid being
killed. Capsular polysaccharide and lipooligosaccharide glycan composition, in particular, play a major role in circumventing
immune response.Theunderstanding of thesemechanisms has opened newhorizons in the field of vaccinology.Nowadays different
licensed meningococcal vaccines are available and used: conjugate meningococcal C vaccines, tetravalent conjugate vaccines, an
affordable conjugate vaccine against the N. menigitidis serogroup A, and universal vaccines based on multiple antigens each one
with a different and peculiar function against meningococcal group B strains.
1. Introduction
The immune system protects humans from attack by
microorganisms such as bacteria, viruses, protozoa, fungi,
parasites, and organisms such as helminths. The skin is
the first barrier and its protective action is enhanced by
bodily secretions, such as sweat and sebum, which exert a
broad antimicrobial activity [1, 2]. The mucous membranes
are protected by external and internal secretions, such as
tears, saliva, and mucus, which contain molecules that can
neutralize bacteria. Tissues such as the skin and mucous
membranes are populated by immune cells, which can act
against the microorganisms that circumvent the first physical
and biochemical barriers.
The immune system is very complex and its defensive
response is subdivided into innate and adaptive responses
[3]. The innate response triggers an immediate, nonspecific,
general action and is activated by typical signs of infection.
The adaptive response is able to develop a highly specific,
extremely accurate action, which is stored in the so-called
immune memory.
This paper provides an overview of the interaction
between the immune system and Gram-negative bacteria
with particular reference to Neisseria meningitidis in the
perspective of developing new vaccines against this pathogen.
2. Gram-Negative Bacteria and Immunity
2.1. Outer Membrane Components. Over thousands of years,
bacteria have developed several mechanisms whereby they
can circumvent the immune system. Specifically, Gram-
negative bacteria possess a complex of envelopes, which
allow the selective passage of nutrients into the cell and the
excretion of metabolic waste outside. Structurally, Gram-
negative bacteria possess an outer membrane (OM), which,
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together with the peptidoglycan and inner membrane (IM),
delimits the periplasm and cytoplasm compartments. Many
molecules of glycolipids, especially lipopolysaccharide (LPS),
emerge from the outer leaflet of theOM,while, from the inner
layer of the OM, lipoproteins reach the peptidoglycan, with
which they engage. Moreover, proteins such as porins cross
the OM; these are very important for the active, passive, and
selective permeability of small molecules, ions, and water [4].
Most porins have a trimeric structure and an oval shape. The
bacterial porins perform many functions; indeed, they help
themicroorganism to adhere to the cells of the host tissue and
to evade the defencemechanisms of the human body, thereby
favouring invasion of the host.They are also able to elicit both
innate and adaptive immunity. Porins can inhibit phagocytic
activity [5] and activate the complement system by means
of both classic and alternative pathways [6]. For instance,
Neisserial porins can activate the transport of NF-𝜅B into
the nucleus of B and dendritic cells (DCs) [7]. The DNA/NF-
𝜅B complex then recalls other proteins, such as coactivators
andRNApolymerase, which transcribe theDNA intomRNA;
finally, this mRNA is exported to the cytosol and translated
into proteins.This leads to a change in the function of the cell;
for example, the cell may begin to produce proinflammatory
cytokines.
Porins are clearly involved in the induction of proin-
flammatory activity, although it is not known which toll-
like receptors recognize them. By contrast, it is known that
LPS stimulates toll-like receptors 2 and 4 [8]. Three distinct
regions characterize LPS, namely, lipid A, which fixes the
molecule to the outer leaflet of the OM, the core polysac-
charide which binds to lipid A by means of a disaccharide
phosphate bridge, and antigen O, which is the most distal
portion.The general structure of LPS is fully conserved, while
the core oligosaccharide is highly variable.
Toll-like receptors are a family of conserved signal trans-
ducers able to induce an innate immune response. To date, at
least 11 mammalian TLRs have been identified. Their stimu-
lation by bacterial components activates the innate immune
response. TLR2 recognizes peptidoglycan, lipopeptides, and
bacterial proteins. However, it is interesting that LPS can
overstimulate the innate immune response, thereby eliciting
inflammation. As a result, the normal defences may not
function correctly. Furthermore, it should be borne in mind
that TLR5 recognizes flagellin, which is the main component
of bacterial flagella [9]. For example, mutations of the TLR4
gene contribute to development of severe meningococcal
infections [10]. In addition, through the recognition of N.
meningitidisDNA, TLR9 exerts strong protection against the
microorganism [11].
2.2. Innate and Adaptive Immune Responses. The innate
immune system is able to detect other conserved microbial
components, called pathogen-associated molecular patterns
(PAMPs), such as nucleic acid structures, lipoteichoic acid,
and peptidoglycan [12]. The pattern recognition receptors
(PRRs) of immune cells include, in addition to TLRs, the
NOD-like receptors (NLRs) and the RIG-1-like receptors
(RLRs), which are able to recognize microbial components
in the cytosol [13]. TLRs, NLRs, and RLRs are able to activate
mitogen-activated protein kinase (MAPK) and the transcrip-
tion of NF-𝜅B factor. A different set of NLRs helps to activate
caspase-1 and the consequent assembly of inflammasomes
[14].
The granulocytes and macrophages are the first cells
that participate in the activation of the innate immune
response. Shortly afterwards, the DCs and natural killer
cells are activated. Specifically, neutrophils produce antimi-
crobial proteins, such as LL37, alpha and beta defensins,
enzymes [15], interferons (IFN) alpha, beta, and gamma, C-
reactive protein, and chemokines, contribute to activating the
complement cascade. Macrophages produce reactive oxygen
species (ROS) (e.g., H
2
O
2
) and reactive nitrogen species
(RNS). Subsequently, DCs, which can also be activated by
TLR2 and TLR4, activate natural killer (NKs) cells [16] and
induce maturation of CD4+ T cells [17–22].
Many bacterial components are able to stimulate the
adaptive human immune response. Porins can activate the
translation of NF-𝜅B in the nucleus of B and DCs, while class
I Pilin E induces highly specific antibodies (Abs) and class
II induces cross-reacting Abs. Furthermore, complement
cascade activation, as well as particularly C3b activation,
opsonizes antigens, thereby enabling APCs to activate the
adaptive response.
3. Neisseria meningitidis and Immunity
3.1. Meningococcal Genome. Meningococci have developed
several “immunoescape” strategies [23], the molecular bases
of which can be understood by taking into account the nature
of the Neisserial genome. Progress in the field of molecular
biology and the introduction of high-throughput technolo-
gies (HTTs) have tremendously advanced our understanding
of the complexity of the Neisserial machinery. By using
sophisticated approaches such as whole-genome sequencing
(WGS) and microarrays, functional genomics investigations
have uncovered the mechanisms that facilitate or hinder N.
meningitidis growth, colonization, and invasion and have
helped to explain its extraordinary intrastrain variation and
adaptation to the environment. Other techniques, such as
genome-wide association studies (GWAS), have shed light
on the pathogen-host interaction and the host’s susceptibility
to the microbe. Genomics and postgenomics have not only
increased our knowledge of the biology and pathogenesis
of N. meningitidis but proved to be extremely useful in
discovering candidate antigens and in developing effective
new vaccines [24].
Being a naturally competent pathogen, N. meningitidis
has a highly dynamic, plastic, and flexible genome with a size
range of only more than 2,000 kilobases [25]. This genome
differs from other microbial genomes in that it lacks some of
the typical two-component systems and sigma factors [26].
Despite being relatively small and compact, it has elaborated
a variety of mechanisms that contribute to explaining its high
adaptability both to host and to environment. Meningococ-
cus is usually polyploid, containing up to 2–5 genomes—
polyploidy being a sign of virulence—while N. lactamica
is monoploid [27]. Neisserial pathogenicity is intrinsically
polygenic [28] and is given by a variety of different pathogenic
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islands (PAIs or genomic islands, GEIs), including gonococ-
cal genetic islands (GGIs) [29] and a recently discovered
meningococcal disease-associated (MDA) island [30].
The nature of the Neisserial chromosome and the pres-
ence of extrachromosomal material contribute to explaining
an important immunoescape strategy, known as structural
or antigenic variation, which consists of camouflage of
the Neisserial repertoire expressed. Basically, it can involve
horizontal or lateral gene transfer (HGT/LGT) (mainly via
transformation and, to a lesser extent, via conjugation and
phage transduction) and allelic exchange/rearrangement of
genes or gene portions taken up from the environment
(Table 1). In addition, as its genome contains multiple copies
of certain genes, for example, opacity factor proteins and
pilins [31], homologous intragenic recombination also results
in frequent surface structural variation.
Moreover, the pathogen hosts a number of prophages,
from the Mu-related family to the phage l-related group
and the family of filamentous M13-like phages [27, 32]. The
most widely studied sites for phage integration are known as
duplicated repeat sequence 3 (dRS3) [26], which belong to
the family of Neisserial intergenic mosaic elements (NIMEs).
Plasmids, such as pJS-A andpJS-B, also play an important role
[33].
Another surface modulation occurs via phase variation,
a process involving the modulation of gene expression via a
mechanism of on/off switching (transition from an expressed
state of the gene to an unexpressed one or vice versa). Besides
this kind of “functional” phase variation, Neisseria can also
undergo a “structural” switch, namely, a transition between
two forms of a gene product. The genes, which are involved
in this strategy, are termed “contingency genes” [26] and can
be coupled and interlinked in structures called phasevarions
(phase-variable regulons) [34], which have a regulatory
function. Phase variation includes a variety of sophisticated
mechanisms [35], such as slipped strand mispairing (SSM)
[36], microsatellite instability [37], and reversible insertion
of minimal mobile elements (MMEs) [38]. Therefore, these
mechanisms can involve single nucleotides (homopolymeric
repeats) or complex nucleotidic structures (short tandem
repeats), occurring either upstream of a gene in the promoter
or within an open reading frame (ORF)/coding sequence
(CDS). Changes upstream of a gene result in modulation
of its transcriptional efficiency and therefore of its final
protein concentration. This is, for example, the case of Opc,
porin A (porA), and fetA genes. Alterations within a gene,
which insert de novo stop codons, alter the full translation
of the gene. An example of this mechanism is provided by
the opa genes and the genes coding for adhesins, such as
nadA [39]. Phase variation of opa genes has been extensively
characterized: they occur in four distinct copies and code for
similar, but not identical, proteins. Phase variation can thus
involve one copy or another, independently of each other, and
can result in eleven variants. In this case, phase variation is
therefore equivalent to antigenic variation. Besides opacity
factor proteins, phase variation can involve up to hundreds
of genes [40]: from the genes coding for pilins [41] or for
proteins involved in genome maintenance and DNA repair
[42, 43] to genes encoding proteins involved in the cell cycle
control and regulation [44], autotransporters [45, 46], or
enzymes like the pilin phosphorylcholine transferase pptA
[47] or the glycosylasemutY [48], among others [49, 50]; the
reader is referred to Table 2, which provides a more detailed
overview of the phase-variable genes. Moreover, new mecha-
nisms leading to phase variations have been discovered [51].
The mechanism implying MMEs involves different kinds
of genetic elements, such as the Correia repeats (CRs) and
the Correia repeat-enclosed elements (CREEs), known also
as the Neisseria miniature insertion sequences (NEMIS) [52,
53], which constitute about 2% of the Neisserial genome
[54]. Other genetic elements are the insertion sequence (IS)
elements, such as IS1016-like, IS1106, IS1301 [55, 56], and
IS1655 [57].
It is worth noting that the number of genes involved
in phase variation is enormously greater than for any other
pathogen studies so far [58]. Some genes are “phasotypes”;
that is to say, they play a role in carriage and are downregu-
lated, favouring host persistence [59].
As already mentioned, in some cases antigenic/structural
variation and phase variation, albeit conceptually two distinct
mechanisms, cooperate in increasing the genetic complexity
of the Neisserial genome. Antigenic variation of LPS, for
example, can derive from phase variation of one or more
enzymes involved in the synthesis of the oligosaccharide
chain by SSM, or by modification of LPS, for example, by
glycosylation [60–62], sialylation [63, 64], or acetylation
[65, 66], which, moreover, confer resistance to neutrophil-
mediated killing.
Thus, both antigenic and phase variations concur in
enabling Neisseria to evade the immune system [26, 27].
3.2. Meningococcal Capsule. LPS and themeningococcal cap-
sule (CP) are the two major virulence factors of N. menin-
gitidis. Specifically, the capsule displays a large variability of
surface antigens, on the basis of which 13 different N. menin-
gitidis serogroups have been identified.The CP contributes in
an important way to the camouflage of the microorganism,
which thus can better circumvent the immune system’s
defences.The clearest expression of this phenomenon is given
by themolecular mimicry [67].This can be seen in the nature
of the polysaccharide CP of serogroup B meningococcus, a
homopolymer of 𝛼2-8-linked sialic acid, which is identical
to a neural cell adhesion molecule, NCAM-1 [68]. Moreover,
lacto-N-neotetraose (L-NNT) in the lipopolysaccharide of
virulent strains is similar to an antigen expressed on red blood
cells [69–73]. Further mechanisms of molecular mimicry
have been recently discovered and described [74].
During the first phase of infection, meningococcus has
to avoid the surface defences of the nasopharynx, such as
the peptides secreted at the mucosal surface [90] and IgA
secretory Abs [90, 196]. To this end, the meningococcus can
aggregate into clusters and produce abundant OM vesicles
(OMVs), thus managing to hide its surface antigens and to
deflect the action of the surface defences from the bacte-
rial cell [196]. In addition, the CP protects Neisseria from
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Table 1: An overview of the most important immunoescape strategies exploited by Neisseria meningitidis.
Immunoescape
mechanism Details References
Structural/antigenic
variation
It consists in the modified expression of domains, which are antigenically different within a clonal
population, by which the pathogen is able to escape the host immunity selection and circumvent
the immune surveillance
It usually involves LOS/LPS, opacity, and pilin proteins
LOS/LPS and opacity factor structural/antigenic variation depends essentially on phase variation
Pili antigenic variations depend on RecA-mediated recombination
[31, 75, 76]
Autolysis It is mediated by OMPLA [77]
Blebbing and
microvesicles formation The blebs originate as evaginations of the outer layer [78]
Capsule switching
Due to microevolution, there is shift from serogroup B to serogroup C, from serogroup C to
W-135, from serogroup Y to W-135, and from serogroup Y to B; nanostructured materials such as
MWNTs and mesoporous silica increase transformational capacity
[30, 79–87]
Capsule modification
For example, modification of lipid A of meningococcal LOS/LPS with phosphoethanolamine
protects Neisseria from neutrophils-mediated killing
Another example is given by the O-acetylation of capsular antigens (LpxL2 gene mutants are
indeed more virulent)
LpxL1 gene mutants activate TLR4 less efficiently
[88]
Genome plasticity HGT/LGT (via conjugation, transduction, and transformation) and homologous intragenicrecombination
[25, 27, 30,
89]
Host modification Neisseria exploits a bacterial sialyltransferase scavenging available host CMP-NANA formodifying LOS/LPS [70]
Molecular mimicry
CP of serogroup B strain is a homopolymer of 𝛼2-8-linked sialic acid and is similar to NCAM-1
L-NNT in the lipopolysaccharide of virulent strains is similar to an antigen on red blood cells
DMP19 acts as a DNA-mimic protein
[67, 69, 71–
74, 90, 91]
Metabolic pathways Examples are iron, lactate, glutamate uptake, utilization, and avoidance of neutrophil oxidationburst, ROS, and RNS [92, 93]
Molecular decoy
FprB has an antigenic subdomain for binding antibodies, which is not essential for the
functioning of the autotransporter; it also blebs with OMPs and LPS/LOS distract the immune
system, directing the response away from the microbe
[94]
Immunotype switch LPS immunotype switches from L3 to L8/L1 by lgtA, lgtC phase variationLOS immunotype can contribute to immunoescape [95, 96]
Phages and prophages The pathogen hosts a number of prophages, from the Mu-related family to the phage l-relatedgroup and the family of filamentous M13-like phages
[25, 30, 89]
Phase variation
High-frequency reversible changes can occur in the length of SSRs (of capsule, LOS, opacity
factor, porin, adhesin, invasin, autotransporter, haemoglobin receptor, DNA mismatch repair, and
pilin genes, termed as contingency genes and organized in modules called phasevarions)
Other repeat sequences can be REP2, CRs, CREEs, and NIMEs
Transposon-like elements can play a role
Phase variation mediates resistance to antibiotics
Phase variation mediates carriage persistence
[50, 52, 59]
Pilin conversion and
modification
Pilin is posttranslationally modified by addition of a glycan, two phosphorylcholines, and a
glyceramido acetamido trideoxyhexose residue [97, 98]
Plasmid Examples of plasmids that can contribute to Neisseria variability are pJS-A, pJS-B [33]
Recruitment of human
components of immune
system
Neisseria escapes complement-mediated killing recruiting and sequestering fH to its surface [91]
Temperature-regulated
defence
RNA thermosensors finely tune the expression of CP components, LOS, and fHBP, thus
protecting against human immune killing [99]
CMP-NANA: cytidine 5󸀠-monophospho-N-acetylneuraminic acid; CP: capsule; CRs: Correia repeats; CREE: Correia repeat-enclosed element; DNA:
deoxyribonucleic acid; fH: complement factor H; fHBP: fH binding protein; HGT: horizontal gene transfer; lgt: prolipoprotein diacylglyceryl transferase; L-
NNT: lacto-N-neotetraose; LOS: lipooligosaccharide; LPS: lipopolysaccharide; LGT: lateral gene transfer; MWNTs: multiwalled nanotubes; NCAM-1: neural
cell adhesion molecule 1; NIME: Neisserial intergenic mosaic element; OMPs: outer membrane proteins; OMPLA: outer membrane phospholipase A; RecA:
recombinase A; REP2: repetitive extragenic palindromic sequence; RNA: ribonucleic acid; RNS: reactive nitrogen species; ROS: reactive oxygen species; SSRs:
simple sequence repeats; TLR: toll-like receptor.
Journal of Immunology Research 5
Table 2: An overview of the most important genes and gene products of Neisseria meningitidis involved in immunoescape mechanisms.
N. meningitidismolecule Immunological role Reference
aniA A nitrite reductase: it protects Neisseria from nitrosative stressduring both colonization and invasion
[90, 100–
102]
App It is phase-variable [103]
ausI/MspA An autotransporter and a serine protease; it is phase-variable [45, 46]
Biofilm (and molecules involved in the biofilm
synthesis, such as autA or hrpA, or optimizing
pathogen survival in biofilm, such as the alpha-peptide
of IgA1 protease, adhC, estD)
Biofilm protects from macrophages; adhC is involved in
S-nitrosoglutathione metabolism and in glutathione-dependent
detoxification system; EstD is involved also in Neisseria
colonization
[104–108]
Blebs (with OMPs and LPS/LOS) and SOMVs They protect from neutrophils-mediated killing and NETs; theydivert the immune response away from the pathogen [78]
Capsule and molecules involved in the capsule
synthesis such as kpsC, kpsS
It activates TLR2 pathway, it increases serum resistance, and it
inhibits the classical pathway of complement [109–111]
Cas9 and the CRISPR-Cas system
CRISPR-Cas9-mediated repression of bacterial lipoprotein
expression facilitates evasion of TLR2 by the pathogen; it is
involved in gene expression and regulation
[112, 113]
cbpA It mediates zinc piracy and protects from nutritional immunity [93]
Cps As a gene, it is involved in the capsule biosynthesis; as RNA, it actsas a thermosensor; Cps gene amplification protects the pathogen [99, 114]
CrgA It is involved in the regulation of pili and capsule expression; itplays a major role in the infectious cycle of Neisseria [114–116]
Css As a gene, it is involved in the capsule biosynthesis; as RNA, it actsas a thermosensor [99]
ctrA, ctrD
As genes, they are involved in the capsule export; as RNAs, they act
as thermosensors; IS1301 in the IGR between sia and ctr operons
mediates resistance to Abs
[99, 117, 118]
cycP It is involved in denitrification metabolism and protects Neisseriafrom nitrosative stress [90, 119, 120]
dam It is involved in phase variation and modulation [42]
dcaC It is phase-variable [40]
dinB A DNA polymerase IV belonging to the SOS regulon: it is involvedin phase variation and modulation [42]
DNA mismatch repair genes (fpg,mutL,mutS,mutY,
recA, recN, uvrD) They are phase-variables; they protect against oxidative stress
[42, 48, 51,
121]
drg It is involved in phase variation and modulation [42]
farA, farB, farR They remove antimicrobial peptides, proteases, lysozyme, andacids from the bacterial cytosol and protect the pathogen [122, 123]
fbpA, fbpB They are involved in phase variation and modulation [51]
Feta It is involved in phase variation and modulation [124–126]
fHbp (formerly known as GNA1870) It is involved in phase variation and modulation; it protectsNeisseria from complement-mediated killing, binding fH [90, 127]
frpA, frpB, frpC They are phase-variable; they can act as a molecular decoy [124, 125,128]
funZ It is a site of bacteriophage insertion; it is phase-variable [49]
fur It is involved in phase variation and modulation; it tunes the geneexpression of virulence genes [102, 129]
ggt It regulates pathogen growth [130]
Ght It is involved in the capsule biosynthesis and in the resistancemechanisms of the pathogen [131, 132]
gltT It favours meningococcal internalization into human endothelialand epithelial cells; it regulates pathogen growth [133, 134]
H.8 AAEAP motifs are target for generation of blocking Abs [135–138]
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Table 2: Continued.
N. meningitidismolecule Immunological role Reference
Haemoglobin-linked iron receptors (hpuA, hpuB,
hmbR) They are involved in phase variation and modulation [43, 139–141]
Hfq A RNA chaperone: it is involved in stress response and virulenceand is a pleiotropic regulator of protein expression [142]
hsdS It is phase-variable [49]
IgA protease
It cleaves secretory IgA, hinders Ab binding and function, and may
play role in biofilm formation; it cleaves lysosomal LAMP1 in
epithelial cells; moreover, it is phase-variable
[122, 142,
143]
katA It confers resistance to RNS, including peroxynitrite (PN), protectsagainst ROS, and detoxifies H2O2
[90, 102, 122,
144]
Laz A lipid-modified azurin: it protects against hydrogen peroxide andcopper toxicity; it promotes Neisseria growth and survival
[135, 138,
145]
lbpA, lbpB
They are involved in iron acquisition and metabolism; they are
phase-variable; moreover, the release of LbpB enables Neisseria to
escape from complement-mediated killing
[90, 122,
146]
lctP Its inactivation results in C3-mediated cell lysis [102, 147,148]
lgtA, lgtB, lgtC, lgtD, lgtE, lgtG
They are involved in LOS biosynthesis and are phase-variable; for
example, lgtA or lgtC phase variation mediates LPS immunotype
switch from L3 to L8/L1
[60]
LOS/LPS It protects from macrophages; strains of the same species producedifferent LOS glycoforms [122]
lptA It adds a phosphoethanolamine group to lipid A and confersresistance to defensins and cathelicidins [90, 149]
Lst LOS sialylation (by the enzyme Lst) prevents complementdeposition and phagocytosis by neutrophils
[122, 150]
mesJ It is phase-variable [49]
Msf It binds to vitronectin; it increases serum resistance [151]
Mip It tunes gene expression [102, 152,153]
misR,misS They are phase-variable; they are involved in capsule regulationand modification [114, 154]
mltA (formerly known as GNA33) It tunes gene expression [155]
mntA,mntB,mntC They protect against oxidative stress [122, 156]
modA,modB They are phase-variable [34]
msrA,msrB They are involved in the methionine sulfoxide reduction and theyrepair oxidized proteins [122, 157]
mtrC,mtrD,mtrE They protect against cationic antimicrobial peptides and toxichydrophobic molecules
[122, 158,
159]
nadA and its regulator nadR
It binds to Hsp90, recruits ARF6 and Rab11, and activates human
monocytes and macrophages, triggering IFN-gamma and R-848
dependent pathways; it interacts with beta1 integrins; it is
phase-variable
[39, 160–
165]
nalP
An autotransporter protease: it cleaves C3, facilitates degradation
of C3b, and enhances Neisserial survival in human serum; it
stabilizes the biofilm; moreover, it is involved in the processing of
other proteases, such as the proteases which release LbpB, whose
release enables Neisseria to escape from complement-mediated
killing; NalP processes also App and IgA1 protease; it has an
important role in the virulence of the pathogen
[24, 102,
166]
Nhba (formerly known as GNA2132) It tunes gene expression [167]
nhhA
It activates TLR4-dependent and independent pathways; it triggers
apoptosis in macrophages; it increases serum resistance and
protects from phagocytosis and complement attack; it is essential
for colonization
[168, 169]
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Table 2: Continued.
N. meningitidismolecule Immunological role Reference
nif S It is phase-variable [49]
nirK It protects Neisseria from nitrosative stress during colonization andinvasion [170, 171]
norB
It favours the pathogen growth, enabling utilization and
consumption of NO during microaerobic respiration, enhances
pathogen survival, protects Neisseria from nitrosative stress during
colonization and invasion, decreases and downregulates the
production of NO-regulated cytokines, such as TNF-alpha, IL-12,
IL-10, CCL5 (RANTES), and CXCL8 (IL-8), and prevents host cell
S-nitrosothiol formation
[100, 119,
120, 170, 172]
nspA It binds to factor H and inhibits AP [122, 173–175]
nsrR It is involved in denitrification metabolism and protects Neisseriaagainst nitrosative stress [176, 177]
oatW, oatY They tune gene expression [178]
Opa
It interacts with CEACAM, promoting endothelial cell attachment
and upregulating endoglin (CD105) and cooperation with 𝛽1
integrins; it elicits innate host defences and actively suppresses
adaptive immune responses that would eliminate the pathogen
[179–184]
Opc
It binds to vitronectin, it inhibits AP, and it increases serum
resistance; it elicits innate host defences and actively suppresses
adaptive immune responses that would eliminate the pathogen
[179–
182, 184]
oxyR It regulates catalase expression and is involved in the protectionfrom oxidative stress [185, 186]
P36 It is involved in Neisserial adhesion. [187]
pacA, pacB They are involved in the composition and regulation ofpeptidoglycan membrane [188]
pglA, pglB, pglG, pglH They are phase-variable [60–62]
Pili
They alter the expression levels of human genes known to regulate
apoptosis, cell proliferation, inflammatory response, adhesion, and
genes for signaling pathway proteins such as TGF-beta/Smad,
Wnt/beta-catenin, and Notch/Jagged
[189]
pilC1 It interacts with mucosal surface and mediates the crossing of theBBB [41, 169]
PilE, pilS They are involved in nonreciprocal recombination-based antigenicvariation [76]
PilE, pilV They bind to CD147 for vascular colonization; they mediate alsoNeisseria internalization [190, 191]
pilP, pilQ They are involved in pilus biogenesis and outer membranestabilization [51, 192]
porA
It binds to fH, C3b, C4b, and C4bp (more strongly under
hypotonic conditions); it increases serum resistance; it is involved
in phase variation
[122, 139,
173]
porB
It inhibits factor H-dependent AP; it interacts with TLR1 and TLR2
and activates I𝜅B, MAPK/MAPKK, and PTK pathways, leading to
CD86 upregulation, to IL-6, IL-12, and TNF secretion in B cells
and DCs, and to IgB secretion in B cells
[122, 173]
pptA It is phase-variable [47]
Ppx
It is an exopolyphosphatase whose mutation protects Neisseria
from complement-mediated killing; it interacts with the AP of the
complement activation
[64]
rmpM It is involved in phase variation and modulation [193, 194]
8 Journal of Immunology Research
Table 2: Continued.
N. meningitidismolecule Immunological role Reference
Sialic acid synthase (neuB, siaA, siaB, siaC, synC) They are phase-variable [102]
sodB, sodC They protect from phagocytosis by humanmonocytes/macrophages [102]
tbpA, tbpB (also known as tbp1, tbp2) They are involved in nutritional immunity [121]
TdfF It is involved in intracellular iron acquisition and is found only ingenomes of pathogen strains [28]
Temperature sensors (such as RNA thermosensors
located in the 5󸀠 UTRs of genes necessary for capsule
biosynthesis, the expression of fHbp, and sialylation of
LOS/LPS)
Activated by coinfecting pathogens, they recruit mechanisms of
resistance and immunity escape [99]
tonB It is involved in nutritional immunity, supplying energy to thepathogen [93]
Uncharacterized proteins (NGO1686, NMB0741,
NMB1436, NMB1437, NMB1438, and NMB1828)
They protect from nonoxidative factors, but their mechanisms are
still not understood; NMB1436, NMB1437, and NMB1438 are
putatively involved in iron metabolism
[122, 195]
Uncharacterized factor (NMA1233) It is involved in phase variation and modulation [26, 51]
xseB It is involved in phase variation [26]
znuD It protects from neutrophils and nutritional immunity [92]
Ab: antibody; AP: Alternative Pathway; ARF6: ADP-ribosylation factor 6; App: adhesion and penetration protein; BBB: blood-brain barrier; cbp: calprotectin
binding protein; CEACAMs: carcinoembryonic antigen-related cell adhesionmolecules; CRISPR: clustered regularly interspaced short palindromic repeats; ctr:
capsule transport apparatus; dam:DNAadeninemethyltransferase; drg: dam replacing gene; fur: ferric uptake regulator; ggt: gamma-glutamyl aminopeptidase;
hsp: heat-shock protein; IgA: immunoglobulin A; lbp: lactoferrin binding protein; lct: lactate permease; LOS: lipooligosaccharide; Mip: macrophage infectivity
potentiator; mltA: membrane-bound lytic transglycosylase A; IGR: intergenic region; Msf: meningococcal surface fibril; Msr: methionine sulfoxide reductase;
NadA: Neisseria adhesion A; NhhA: Neisseria hia homologue A; oat: O-acetyltransferase; OMV: outer membrane vesicle; opa: opacity-associated protein a;
opc: opacity-associated protein c; pac: peptidoglycan O-acyltransferase; pil: pilin; por: porin; RNA: ribonucleic acid; RNS: reactive nitrogen species; Sod:
superoxide dismutase; SOMVs: spontaneously released OMVs; Tbp: transferrin-binding protein; TLR: toll-like receptor; UTRs: untranslated regions; uvr:
ultraviolet resistant.
cationic antimicrobial peptides (CAMPs), including catheli-
cidin [196]. Conversely, the presence of capsular polysaccha-
ride restrains the invasion and colonization of the nasopha-
ryngeal barrier by hiding the adhesins and invasins of the
meningococcus [143, 158]. On the other hand, the presence of
the capsule may allow the microorganism to pass unharmed
through the intracellular environment by exploiting the sys-
tem of cell microtubules, at least in the case of serogroup BN.
meningitidis [197].Moreover, the CP is essential formeningo-
coccal growth and survival in the bloodstream and cere-
brospinal fluid, increasing serum resistance. During the dif-
ferent stages of infection, the capsule may hinder or promote
the survival of N. meningitidis in the human host; indeed,
the microorganism can modulate the production of capsule
components, which depends on 4 genes, three of which—
siaA, siaB, and siaC—are situated in the cps locus. The siaD
gene induces the production of polysialyltransferase, which
allows the polymerization of sialic acid. For instance, in
the early stages of infection, the production and assembly
of sialic acid are downregulated [198]. Another example of
polysialyltransferase system is given by oatWY [178].
In addition to the above-mentioned actions, the most
important virulence activity of the CP is probably the signif-
icant impairment of both Neisserial adherence to DCs and
the phagocytic killing of bacteria; indeed, the CP inhibits
both the opsonic and the nonopsonic phagocytosis of N.
meningitidis [199]. It prevents the formations of effective Abs
against N. meningitidis.
CP downregulates both classical and alternative com-
plement pathways and prevents the proper insertion of
the membrane attack complex (MAC) [200, 201]. LPS also
contributes to inhibiting MAC deposition [201, 202].
Moreover, CP switching contributes to escaping detection
and killing.This is a complex phenomenon due to microevo-
lution and usually involves Neisserial strains expressing sialic
acid (e.g., the shift from serogroup B to C, from serogroup C
to W-135, from serogroup Y to W-135, and from serogroup
Y to B) [79–82, 203]. The molecular basis is provided by the
allelic replacement of the sialic acid CP polymerase.
Surprisingly, nanostructured materials such as multi-
walled carbon nanotubes (MWNTs) and mesoporous silica
have been found to increase Neisseria’s transformational
capacity [83, 84].
3.3. Major and Minor Adhesion Mechanisms of N. menin-
gitidis. N. meningitidis possesses a multifaceted system of
adhesins, such as pili and other systems of adhesion (i.e.,
opacity-associated proteins OpA and OpC). Adhesion is
probably a coordinated process mediated first by pili, which
are composed of several proteins; themost important of these
is Pilin E (PilE) [204], but Pilin C (PilC) [205] and the secretin
PilinQ (PilQ) [206] have also been described. PilE is themain
constituent of the Neisseria type IV pilus. In 1984, Diaz et
al. identified proteins I and II as the main components of
the type IV pili and noted that Abs against protein I were
highly specific [207]. Subsequently, Pilin E was classified as
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belonging to class I and class II. Class I Pilin E is highly
variable, while class II Pilin E is highly conserved [208, 209].
For this reason, class II Pilin E has been suggested as a can-
didate antigen for a vaccine against meningococci [147]. The
regulation of pilin genes is quite complex [97, 115, 116, 190].
Other components are as follows: pilV [210], pilP, pilD
(a prepilin-processing leader peptidase), pilF and pilT (traffic
NTPases), pilG (involved in the pilus assembly), pilM (pilus
biogenesis protein), and pilW (involved in the pilus stabiliza-
tion) [148], among others.
Although the interactions between type IV pili and cel-
lular receptors are not completely known, they may interact
with a membrane cofactor protein, named CD46 receptor,
and with alpha 1 and alpha 2 integrins [211]. However, it is
known that pili contribute to the aggregation of Neisserial
cells [212]. This fact, associated with the ability of pili to act
as a signalling protein by interacting directly with the 𝛽2-
adrenergic receptor, contributes to the depletion of junction
proteins, thus helping meningococcus to pass through the
epithelial and endothelial cells and, subsequently, to cross the
blood-brain barrier (BBB) [75, 213].
Although pili are essential to the first phase of Neisserial
adhesion to the cells of the airways, other adhesionmolecules,
such as LPS and porin A, intervene to strengthen the
microbial bond. In particular, OpcA and OpcC appear to
be very important; indeed, OpcA binds carcinoembryonic
antigen cell adhesion molecules (CEACAMs), heparan sul-
phate proteoglycan (HSPG) and integrins [179–183, 214]. Opc
proteins can combine with HSPGs and, through vitronectin
and fibronectin, with their integrin targets. Furthermore,
Opa proteins are able to elicit innate human defences that
favour the survival of N. meningitidis, while actively sup-
pressing adaptive immune responses that would eliminate the
pathogen [184]. The variability of the expression of different
Opa proteins could play a major role in prolonging the state
of infection by circumventing the humoral host immune
response [215].
The adhesion and penetration protein (app) [103], which
is a member of the autotransported family of secreted
proteins, owes its name to its ability to adhere to human
cells, thereby favouring the entry of Neisseriae. To circum-
vent the immune system, meningococci possess formidable
machineries that allow them to secrete proteins in dif-
ferent manners; in particular, Neisseriae mainly use the
autotransporter pathway (also known as type V secretion
system) [216]. The first-described protein belonging to the
autotransporter superfamily was an IgA protease from N.
gonorrhoeae [217]. MspA (meningococcal serine protease A)
is another putative autotransporter protein. Not all strains
of Neisseria gonorrhoeae/meningitidis possess the gene for
MspA/AusI (also known as NMB1998). However, Turner et
al. [218] demonstrated that convalescent sera from subjects
affected by serogroupB invasive disease recognized theMspA
antigen. NhhA (Neisseria hia/hsf homologue A, also known
as Hsf) and Neisserial adhesin A (NadA) also belong to
the autotransporters. Nhha contributes to bacterial adhe-
sion by binding heparin sulphate and laminin. In addition,
through the activation of caspase, NhhA increases the rate of
macrophage apoptosis [168, 219]. NadA, which is expressed
by 50% of virulent strains [160], but only by 5% of the strains
isolated from carriers, is of particular interest because it is
one of the components of the 4CMenB (Bexsero) vaccine and
binds beta1 integrins [220].
3.4. N. meningitidis: Avoidance Mechanisms against Reactive
Oxygen Species (ROS), Reactive Nitrogen Species (RNS), and
Antimicrobial Peptides (AMPs). When in contact with the
mucosa of the nasopharynx, N. meningitidis can implement
several strategies of adhesion, but it must overcome many
barriers of innate immunity.We have alreadymentioned how
the capsule allows bacteria to mitigate the activity of DCs.
However, it must elude other substances, such as the reactive
oxygen species and reactive nitrogen species produced by
macrophages and the antimicrobial peptides produced by
activated neutrophils. As already mentioned, the capsule
protectsN.meningitidis from LL-37 cathelicidin, but LPS also
contributes to the resistance of the bacterium against this
cathelicidin [156].
Furthermore, the toxic action of ROS is neutralized by
the secretion of enzymatic proteins, such as catalase and
superoxide dismutase [144, 149, 221]. The gene that codes for
catalase is katA and is regulated byOxyR [185, 186, 222], while
SodB and SodC code for superoxide dismutase [223]. Laz,
a lipid-modified azurin, protects the pathogen against H
2
O
2
and cupper toxicity [135–138, 145, 176].
In addition, N. meningitidis possesses genes, which
encode enzymes able to exert a denitrification action, such
as aniA, CycP, nirK, nsrR, and norB. They favour the growth
of the pathogen, enabling utilization and consumption of NO
during microaerobic respiration, enhance pathogen survival,
and protect Neisseria from nitrosative stress during colo-
nization and invasion by preventing host cell S-nitrosothiol
formation. Moreover, they reduce and downregulate the
production of NO-dependent cytokines, such as TNF-alpha,
IL-12, IL-10, CCL5 (RANTES), and CXCL8 (IL-8) [100, 101,
119, 120, 130, 157, 170, 172, 177, 224].
Contemporarily, already at the level of the mucosa, the
microorganism must resist the complement system.
Another interesting mechanism is the strategy whereby
N. meningitidis escapes the attempts of the host to sequester
nutrients essential for growth and survival of the pathogen.
This process has been termed “nutritional immunity” [131,
139]. The microbe is endowed with OM receptors (such as
HmbR, HpuA orHpuB, TbpA or TbpB, and TdfF) for acquir-
ing iron and other importantmetals [93, 124, 125, 128, 129, 140,
195, 225]. ZnuD is a high-affinity zinc uptake receptor, which
plays an important role in enabling the pathogen to evade
neutrophil-mediated killing [226, 227]. CbpA, a receptor
for calprotectin, a protein released by neutrophils during
inflammatory processes, is upregulated whenN. meningitidis
suffers from zinc limitation [226, 227]. Further examples
of metabolic enzymes involved in nutritional immunity are
glutamate transporters ormolecules taking part in the carbon
cycle [132–134, 228–230].
3.5. HowMeningococcus Circumvents the Complement System.
Three pathways can activate the complement functions,
namely, the classic pathway, the alternative pathway, and
10 Journal of Immunology Research
the lectin pathway. All three of these pathways contribute to
the transformation of C3 to C3b [231].
The alternative pathway acts by comparing self- with non-
self-antigens and is activated by anything that differs from the
markers of host cells. Specifically, factor H recognizes host-
associated molecular patterns (HAMPs). Properdin, first
identified in 1959, is another protein that can directly activate
the alternative pathway of the complement system [232]. It
has been demonstrated that properdin deficiency favours
recurrent episodes of N. meningitidis infection [233].
Meningococci produce three different variants (1, 2, and
3) of a protein that binds factor H.This protein, named fHbp
(factor H binding protein) or GNA1870, blocks activation of
the alternative pathway of the complement system. Indeed,
by surrounding themselves with fHbp, N. meningitidis cells
capture and inactivate factor H. Thus, it is easy for the
microorganism to survive and reproduce, especially in the
bloodstream and cerebrospinal fluid. Hence, it is important
that the 4CMenB (Bexsero) vaccine contains variant 1 of this
protein, which is often expressed by virulent meningococcal
strains [228]. Another vaccine (Trumenba), recently licensed
in the USA, contains recombinant variants 1 and 2 of fHbp
from N. meningitidis serogroup B, A and B subfamilies (A05
and B01, resp.) [234, 235]. The proteins are produced by
exploiting an advanced genetic engineering technique, using
E. coli as a vector.
3.6. The Adaptive Immune Response against Neisseria menin-
gitidis. Microorganisms such as N. meningitidis are able to
changemany exposed surface proteins, while the polysaccha-
rides, which constitute the capsule, are T-independent (TI-2)
antigens and can activate B cells directly, without the inter-
vention of theMHC.However, TI-2 antigens donot induce an
efficient secondary response and do not induce the produc-
tion of avid immunoglobulins. Rather, they induce the pro-
duction of short-lived Abs belonging to the IgM class [236].
In addition, it is important to consider that, in infants and
children, the development of the immune system is a dynamic
process, which begins in utero and continues for months and
even years after birth. This explains why many components
of the immune system are inefficient or partially efficient in
infancy and early childhood [237–239]. For this reason, most
cases of meningitis and sepsis from N. meningitidis occur
under the age of 4 years and particularly in the first year of life.
The critical role of bactericidal Abs against the exposed
surface antigens of N. meningitidis has been demonstrated
by several studies. Indeed, Goldschneider et al. [240] showed
that only individuals without bactericidal Abs contracted the
clinical disease. In addition, the successful therapeutic use of
immune sera, which markedly reduced lethality when first
implemented by Flexner [241], has shown the central role of
these Abs in protecting against invasive disease. The opsonic
activity of Abs is also very important in the protection
against and the recovery from meningococcal disease, as is
demonstrated by the role of neutrophils, macrophages, and
DCs in combating N. meningitidis. It is also well known that
the cerebrospinal fluid of patients contains large numbers
of neutrophils full of microorganisms. These clusterings
of neutrophils are known as neutrophil extracellular traps
(NETs) and massively release cathepsin G. N. meningitidis
circumvents these traps by blebbing spontaneously released
OMVs (SOMVs). Other strategies that the pathogen exploits
aremodification of lipidA of LPSwith phosphoethanolamine
protected and upregulation of ZnuD [92].
The adaptive immune response has been studied in car-
riers and during both the invasive period leading to clinical
meningitis and the convalescence period. T cell response is
“two-faced”; while proinflammatory T cellsmay indeed blunt
the invasive power of the pathogen, the induction of the
Treg response, which is able to limit virulence, carries the
price of the reduced effectiveness of the protective response,
especially in children [242]. During infection, increased
meningococcal antibody titres can be detected from the 4th
day, peaking at the end of the third week or the beginning of
the fourth week and showing a correlation with the severity
of the disease and the age of the patient. In the acute period of
the disease, the number of T cells generally drops, while that
of B cells increases; by the end of the second week, IgG levels
decline and IgM levels rise [243]. In particular, abnormalities
in T cell response can be detected, such as an elevated
percentage of CD25+ and HLA-DR+ T cells, an increase in
CD4+ CD45R+ (suppressor-inducer) cells, with subsequent
expression of activation antigens, and a decrease in CD4+
CDw29+ (helper-inducer) cells [244]. During convalescence,
an age-associatedTh response can be observed: specifically, a
Th1 response (low IL-10/IFN-𝛾 ratio) and a highly prolifera-
tive Th2 response (higher IL-10/IFN-𝛾 ratio) can be detected
in younger and older patients, respectively [245]. Generally,
a significant CD4+ T central memory response, with serum
bactericidal antibodies, a marker of protective immunity, can
be found [246]. However, the above-mentioned age-related
mucosal T effector/memory cell responsemay also be present
without bactericidal antibodies [247].
3.7. Other Immunoescape Strategies. Temperature fluctuation
plays an important, although underscored, role in microbial
pathogenesis, colonization, invasion, and host evasion. In
contrast to mammals that maintain constant body temper-
ature, pathogens’ and other animals’ temperature oscillates
on a daily basis. Loh and collaborators [99] have identified
the molecular bases of this temperature-dependent strategy.
They have studied three RNA thermosensors located in the
5󸀠 untranslated regions (UTRs) of genes involved in the
CP biosynthesis, the expression of fHbp, and sialylation of
LOS/LPS. Increased temperature (e.g., during inflammation
by coinfecting pathogens, such as influenza virus) “alarms”
the meningococcus and triggers its defence mechanisms
against human immune killing. This could be a key deter-
minant for the transformation of a symbiont pathogen into a
virulent one. However, the precise nature of this mechanism
remains elusive.
Clustered regularly interspaced short palindromic
repeats- (CRISPR-) Cas9 is another molecular tool that
Neisseria can use in order to divert immune surveillance. It is
an intrinsically ambivalent device, since, on one hand, being
involved in gene expression and regulation, it restricts the
possibility of editing the Neisseria genome via HGT/LGT or
the insertion of exogenous nucleic material, and therefore it
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limits the microbial variability. On the other hand, CRISPR-
Cas9-mediated repression of bacterial lipoprotein expression
facilitates evasion of TLR2 by the pathogen [112].
Another mechanism is the molecular decoy, with which
the microbe deceives the human immune system. For exam-
ple, fprB has an antigenic subdomain for binding antibodies,
which is not essential for the functioning the autotransporter
[94].
The example of fprB is useful to show how Neisseria can
use concurrently the previously described immunoescape
strategies: fprB is subject to a high degree of antigenic varia-
tion, is a phase-variable gene, is involved in nutritional immu-
nity, and moreover exploits a molecular decoy. Neisserial
carbohydrates, mimicking host carbohydrates, circumvent
immune system and at the same time exploit their mimicry
to recruit fH [91].
4. Meningococcal Vaccines
4.1. Polysaccharide Vaccines. As at least six meningococci are
pathogenic in humans, the development of meningococcal
vaccines has been a challenge. The first step towards solving
the problem was to find a common denominator among
antigens that showed high variability. In 1969, Gotschlich et
al. [248] correctly put the first imperfect piece of the puzzle in
place by demonstrating the possibility to extract the capsule
polysaccharide. However, although high molecular weight
groups A and C meningococcal polysaccharides proved
immunogenic in adults [249–251], important limitations
of this vaccine emerged in subsequent years. Indeed, while
both group A and group C vaccines proved effective in
USA and Italian recruits [252, 253] after one administration,
they displayed only short-term efficacy in older children
and adults. Moreover, vaccines against serogroup C did
not prevent disease in infants, and the efficacy of group A
vaccines in children under 1 year of age was unclear. The
immune response occurred 10 days after vaccination. In
schoolchildren and adults, one dose of these vaccines seemed
to provide protection for at least 3 years [254].These findings
are explained by the characteristics of the antigens contained
in the vaccines. Indeed, polysaccharides with repeating
epitopes induce an immune response with the following
characteristics [255, 256]:
(i) The response occurs between the ages of 3 and 18
months but is variable; in children less than 2 years
of age, the response is usually poor;
the affinity maturation of the Abs does not occur.
(ii) The immunologic memory is not stimulated.
(iii) Almost all (>90%) Abs produced belong to the IgM
class and are produced in the spleen [257, 258]. Fur-
thermore, several studies have suggested that vacci-
nation with large amounts of polysaccharides induces
immune tolerance towards these antigens [259].
4.2. Polysaccharide Conjugate Vaccines. Three immunogenic
carrier proteins are generally used inpolysaccharide conju-
gate vaccines, namely, diphtheria or tetanus toxoid, CRM197
(a nontoxic variant of diphtheria toxin obtained bymolecular
biology), and a complex of outer membrane protein (OMP)
mixture from N. meningitidis. The toxoids were selected
as carriers, firstly because of their immunological potency
and secondly because if the recipient had previously been
immunized with the toxoid, a booster effect was predictable.
Moreover, under particular conditions, suppressive effects
can also occur. The conjugate vaccine against N. meningitidis
serogroup C had great success in several countries (UK,
Netherlands, Spain, Italy, etc.) [260]. Today, tetravalent con-
jugate vaccines ACWY are also available in both the USA and
Europe [260–262].
4.3. Vaccines against N. meningitidis Serogroup B. The most
difficult problem was to prepare a vaccine against N. menin-
gitidis serogroup B strains. Indeed, the maximum expression
of camouflage is found in the capsule of these strains.
Specifically, the polysaccharide of serogroup B meningo-
coccal strains is a homopolymer of sialic acid residues
and has structural similarities to brain glycoproteins. For
this reason, it was impossible to prepare a polysaccharide
antimeningococcus B vaccine. To overcome this obstacle,
OMVs-vaccines were developed and used during epidemics
caused byN.meningitidis serogroupB strains.However, given
the high variability of the proteins, such as porins, present
in OMVs, these vaccines were effective only against very
specific epidemic hypervirulent strains [263, 264]. In order to
develop a vaccine against meningococcus B, other strategies
were therefore implemented.
The most promising results were obtained through
reverse vaccinology.This involves identifying the antigens for
the vaccine not in the classic way—that is, from the com-
ponents of the bacterium—but instead from the genes that
express the proteins with the best characteristics to be good
antigens for the vaccine. To obtain a universal vaccine against
serogroup B meningococcal strains, complex bioinformatics
softwarewas also applied. Following the complete sequencing
of the meningococcus B genome [265], researchers at Novar-
tis Vaccines and Diagnostics identified 600 ORFs, which
expressed proteins that are exposed on the surface of the
bacterial cell. Subsequently, 350 proteins were successfully
expressed in E. coli, purified, and used to immunize mice.
Later, 28 novel protein antigens able to elicit Abs with
bactericidal activity were identified. Finally, three of these
28 proteins were selected, namely, NHBA (GNA2132, fused
withGNA1030 protein), fHbp (fusedwithGNA2091 protein),
and nadA. NHBA (Neisseria heparin binding antigen), which
is present in virtually all strains, binds heparin, which may
increase the serum resistance of bacteria. fHbp (factor H
binding protein) binds factor H, which enables the bacterium
to survive in theblood [266, 267], thereby blocking the alter-
native pathway of the complement system. nadA (Neisserial
adhesin A) promotes adherence to and invasion of human
epithelial cells [161, 162]. In addition, the vaccine developed
by Novartis Vaccines and Diagnostics contains a fourth
component, namely, the vesicle of the OM from the New
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Zealand strains, which contain porin 1.4. Theoretically, this
vaccine should elicit bactericidal Abs against the following:
(i) NHBA, thus increasing the bactericidal activity of the
serum.
(ii) fHbp, thus exposingN. meningitidis to the alternative
pathway of the complement system.
(iii) NadA, thus hindering the adherence of N. meningi-
tidis to epithelial cells.
(iv) Porin A 1.4 and other components of the mixture
of proteins contained in OMVs; indeed, OMVs can
enhance the immune response by functioning as a
conjugate complex of proteins or, rather, a complex
of adjuvants.
Several clinical trials have demonstrated the immunogenicity
and safety of this vaccine, also named 4CMenB, in infants,
children, adolescents, and adults [268, 269]. Consequently
the vaccine has been approved by the EMA and named
Bexsero [270]. It has also been approved by several national
drug agencies (such as FDA), including the Agenzia Italiana
del Farmaco (AIFA, Italian National Agency for Drugs) [271].
Owing to the wide variability of Neisserial antigens, a
particular laboratory test (MATS) has been developed to
estimate the potential effectiveness of the vaccine. Studies
conducted worldwide have shown the potential effectiveness
of Bexsero, which has been estimated at 87% in Italy [85].
Trumenba was approved for individuals aged 10 to 25
years in the USA in October 2014 [85]. The potential of the
vaccine antigen was tested in the laboratory [272] and on a
murine model [273, 274]. The immunogenicity, safety, and
tolerability of this vaccine were investigated in a randomized
controlled trial in infants aged 18–36 months, who were
subdivided into three cohorts (receiving 20-, 60-, and 200-
𝜇g rLP2086 dose, resp.) and matched with two control
groups: one vaccinated against hepatitis A virus (HAV)
and the other with a saline placebo. After the vaccination
cycle, seroconversions against Neisserial strains expressing
LP2086 variants homologous to the vaccine antigens were
found in 61.1–88.9% of toddlers and against strains expressing
heterologous LP2086 variants in 11.1–44.4%.Adverse reaction
rates were negligible and the vaccine proved to be safe and
well tolerated [275]. However, another randomized phase 1/2
clinical study found high fever rates in toddlers receiving one
20- or 60-𝜇g rLP2086 dose (64% and 90%, resp.) [276].
In a randomized study performed in the USA and Europe
in a sample of adolescents (11–18 years of age), Trumenba
proved to be highly immunogenic. The proportion of vacci-
nees with human serum bactericidal activity (h-SBA) titres
with a ≥4-fold rise against hypervirulent Neisserial strains
with different variants of fHbp was in the range of 75–100%.
In another randomized clinical study, carried out inAustralia,
the safety and immunogenicity of the vaccine were assessed
in 60 healthy adults (18–40 years of age) who received 120 𝜇g
doses at 0, 1, and 6 months. The percentage of seroprotected
vaccinees was 94.3% against the homologous strains and 70–
94.7% against the heterologous strains. The vaccine was well
tolerated [277, 278].
As fHbp is also expressed by Neisserial serogroups
other than B, the anti-fHbp Abs elicited by rLP2086 might
exert a bactericidal effect on meningococci, such as those
against N. meningitidis serogroup C, as proved by Harris
and collaborators [279] and by Konar and colleagues [280].
Moreover, there is some evidence that Trumenba could, at
least in part, have an effect on carriage and reduce the risk
of acquiring some hypervirulent strains [281].
4.4. NewVaccines. The currently availableNeisseria vaccines,
described in the previous paragraphs, are reported and
summarized in Table 3.
The elucidation of immunoescape strategies and
genomics have enabled scholars to discover new potential
vaccine candidates, like NMB0928 [282] or NMB1468 [283],
FrpB/fetA [125], LbpA and LbpB [284], adhesin complex
protein (ACP) [285], NspA [286, 287], MIP [152], ZnuD
[93], PilE [76] and PilQ [288], IgA protease [289], T cell
stimulating protein A (tspA) [289], or the CP polymerase of
Neisseria serogroup X [290], among others [291].
Reverse vaccinology has proved to be a promising
approach, enabling researchers to develop the effective vac-
cine Bexsero. New highly integrated approaches, which
combine genomics with postgenomics, are leading to next-
generation vaccines. A combination of reverse and forward
vaccinology techniques, such as immunoproteome investi-
gation via combined cell surface immunoprecipitation and
mass spectrometry (MS) [153], and new bioinformatics
strategies, such as the protectome approach [292], are promis-
ing in identifying highly conservedmotifs in known bacterial
protective antigens and using them for the design of effective
universal vaccines [293, 294].
5. Conclusions
Thedevelopment of effective vaccines against meningococcal
disease has been a long andhard struggle. Early efforts yielded
only partial results, with the creation of polysaccharide
vaccines [295]. Subsequent research, however, led to the
production of the conjugate vaccines [296]. Today, we have
the conjugate meningococcal C vaccines [297], an afford-
able conjugate vaccine against N. meningitidis serogroup A
(MenAfriVac) [298, 299], the tetravalent conjugate vaccines
[270], and, finally, two “universal” vaccines against meningo-
coccal group B strains [300, 301]. The critical rate of coverage
required in order to eliminate the disease is probably not
among the highest [302]. Indeed, the conjugate vaccine for
serogroup C has resulted in dramatic reductions of cases of
the disease [303] and created herd immunity that seems to
have had a significant effect on the carrier status of adoles-
cents and young adults.Thus, the prospect of dominating this
very serious disease lies decidedly in the medium term.
However, it must be borne in mind that we are immersed
in a constellation of Neisseriae, whose only survival niche
is man. Although Neisseriae such as N. lactamica, N. sicca,
N. elongata, N. cinerea, and N. flavescens are usually able
to establish silent infection in normal humans, it is not
inconceivable that, given the microorganism’s great capacity
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Table 3: An overview of the currently available Neisseriameningitidis vaccines.
Vaccine Manufacturer Serogroups Licensed age group Administrationschedule Components details
AC Vax GlaxoSmithKline,UK A, C 2 y+ Single dose
50𝜇g each of meningococcal
polysaccharides
ACWY Vax GlaxoSmithKline,UK
A/C/Y/W-
135
2 y+; can be given
also at 2mo+, even
though less
protective against
C, Y, and W-135
Single dose 50𝜇g each of meningococcalpolysaccharides
Bexsero
(4CMenB)
Novartis Vaccines
and Diagnostics B 2mo–17 y
Complex dose schedule
depending on age: 3
doses + booster for
2–5mo; 2 doses +
booster at 6–23mo; 2
doses at 2+ y
50 𝜇g of each recombinant NHBA,
NadA, fHbp fusion proteins,
OMVs from strain NZ98/254
containing the PorA P1.4 (25 𝜇g),
adsorbed on 0.5mgAl3+
HexaMen and
HexaMix
National Institute
for Public Health
and the
Environment,
Bilthoven,
Netherlands
B —
2, 3, and 4mo, a
booster dose at
12–18mo
OMV from two recombinant
engineered strains, each of which
expressed three different PorA
subtypes (P1.5-2, 10; P1.12-1, 13;
P1.7-2, 4; P1.19, 15-1; P1.7, 16; and
P1.5-1, 2-2)
Menactra
(MenACWY-DT) Sanofi Pasteur
A/C/Y/W-
135 9mo–55 y Single dose
4𝜇g each of meningococcal
polysaccharides conjugated to
48𝜇g of a diphtheria toxoid
protein carrier
MenAfriVac
(MenA-TT)
Serum Institute of
India A 1–29 y Single dose
10𝜇g of meningococcal group A
polysaccharides conjugated to 10
to 33 𝜇g tetanus toxoid
MenBvac
National Institute
for Public Health,
Norway, and
Novartis
B — 3 doses (interval5–12w)
OMVs from the strain 44/76
adsorbed on Al3+
MencevaxA GlaxoSmithKlineand RIT, Belgium A 2 y+ Single dose
50 𝜇g of meningococcal group A
polysaccharides
No conjugation
MencevaxAC GlaxoSmithKline A, C 2 y+ Single dose
50𝜇g each of meningococcal
group polysaccharides
No conjugation
MencevaxACY GlaxoSmithKline A, C, Y 2 y+ Single dose
50𝜇g each of meningococcal
group polysaccharides
No conjugation
MencevaxACYW GlaxoSmithKline A/C/Y/W-135 2 y+ Single dose
50𝜇g each of meningococcal
group polysaccharides
No conjugation
Mengivac A + C
(MenPS) Sanofi Pasteur A, C — —
50 𝜇g of meningococcal group C
polysaccharides
MenHibrix
(HibMenCY-TT) GlaxoSmithKline C, Y 6w–18mo 2, 4, 6, and 12 to 15mo
Meningococcal groups C and Y
polysaccharides conjugated to
tetanus toxoid
Meningitec
(MenC-CRM)
Wyeth Vaccines,
Canada, UK, and
Australia
C 2mo+ 3 doses at 2–12mo, 1dose at 12mo+
10𝜇g of meningococcal group C
polysaccharides conjugated to
15𝜇g CRM197
Meninvact Sanofi Pasteur C 2mo+ 2 doses at 2–12mo, 1dose at 12mo+
Meningococcal group C
polysaccharides conjugated to
CRM197
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Table 3: Continued.
Vaccine Manufacturer Serogroups Licensed age group Administrationschedule Components details
Menitorix
(Hib-MenC-TT) GlaxoSmithKline C 6w–12mo Booster at 1-2 y
Meningococcal group C
polysaccharides conjugated to
tetanus toxoid
Menjugate
(MenC-CRM)
Novartis Vaccines
and Diagnostics C 2mo+
3 doses at 2–12mo; 1
dose at 12mo+
10𝜇g of meningococcal group C
polysaccharides conjugated to 12.5
to 25 𝜇g CRM197
Menomune Sanofi Pasteur A, C 2 y+ Single dose
50𝜇g each of meningococcal
group polysaccharides
No conjugation
Menomune Sanofi Pasteur A/C/Y/W-135 2 y+ Single dose
50𝜇g each of meningococcal
group polysaccharides
No conjugation
Menovac Finlay Institute A/C/Y/W-135 2–55 y Single dose
Meningococcal group
polysaccharides
Menveo
(MenACWY-
CRM197)
Novartis Vaccines
and Diagnostics
A/C/Y/W-
135 2–55 y Single dose
10𝜇g of meningococcal group A
polysaccharides and 5 𝜇g of
meningococcal groups C, Y, and
W-135 polysaccharides conjugated
to CRM197
MeNZB
Institute for
Public Health,
New Zealand,
Chiron, Novartis
B — — OMVs from strain P1.7b, 4
NeisVac-C
(MenC-TT) Baxter BioScience C 2mo–65 y
2 doses at 2–12mo
(with an interval of at
least 2mo), 1 dose at
12mo+
10𝜇g of meningococcal group C
polysaccharides conjugated to
tetanus toxoid
Nimenrix GlaxoSmithKline A/C/Y/W-135 1 y+ Single dose
5 𝜇g each of meningococcal group
polysaccharides conjugated to
44𝜇g tetanus toxoid
NmVac4
JN-International
Medical
Corporation
A/C/Y/W-
135 2–55 y Single dose
50𝜇g each of meningococcal
group polysaccharides
Trumenba Pfizer B 10–25 y 3 doses (0–2–6mo) 120 𝜇g of recombinant fHbpadsorbed on 0.25mg Al3+
Zamevax ImunoloskiZavod, Croatia A, C — — No conjugation
CRM197: cross-reacting material 197; fHbp: factor H binding protein; mo: month; NadA:Neisseria adhesion A; NHBA: Neisseria heparin binding antigen, also
named GNA2132; OMV: outer membrane vesicle; PorA: porin A; w: week; y: year; Al3+: Aluminum.
for genetic variation, nonpathogenicNeisseriamight become
hazardous to humans [304].
The challenge is still open.
Abbreviations
Abs: Antibodies
ACP: Adhesin complex protein
AIFA: Agenzia Italiana del Farmaco (Italian
National Agency for Drugs)
AMPs: Antimicrobial peptides
AP: Alternative Pathway
app: Adhesion and penetration protein
ARF6: ADP-ribosylation factor 6
BBB: Blood-brain barrier
C3: Human complement 3 component
C3b: Human complement 3b component
C4: Human complement 4
C4bp: Human complement 4b binding protein
CAMPs: Cationic antimicrobial peptides
cas: CRISPR-associated
cbp: Calprotectin binding protein
CCL: Chemokine (C-C motif) ligand
CD: Cluster of Differentiation (CD4, CD25,
CD45R, CD86, CD105, CD147, CDw29)
CDS: Coding sequence
CP: Capsule
CEACAMs: Carcinoembryonic antigen related cell
adhesion molecules
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CMP-NANA: Cytidine monophosphoacetyl N-Acetyl-
neuraminic acid
CRs: Correia repeats
CREEs: Correia repeat-enclosed elements
CRISPR: Clustered regularly interspaced short
palindromic repeats
CRM197: Cross-reacting material 197
CRP: C-reactive protein
CXCL: Chemokine (C-X-C motif) ligand
DCs: Dendritic cells
dam: DNA adenine methyltransferase
DNA: Deoxyribonucleic acid
drg: Dam replacing gene
dRS3: Duplicated repeat sequence 3
E. coli: Escherichia coli
EMA: European Medicines Agency
FDA: Food and Drug Administration
fH: Factor H
fHbp: Factor H binding protein
fur: Ferric uptake regulator
GEI: Genomic island
GGI: Gonococcal genetic island
ggt: Gamma-glutamyl aminopeptidase
GNA: Genome-derived neisserial antigen
(GNA33, GNA1030, GNA1870, GNA2091,
GNA2132)
GWAS: Genome-wide association studies
HAMPs: Host-associated molecular patterns
HAV: Hepatitis A virus
HGT: Horizontal Gene Transfer
HLA: Human leukocyte antigens
hpu: Haemoglobin-haptoglobin utilization
h-SBA: Human serum bactericidal activity
HSP: Heat-Shock Protein
HSPG: Heparan sulphate proteoglycan
HTTs: High-throughput technologies
IFN: Interferon
IgA: Immunoglobulin A
IgG: Immunoglobulin G
IgM: Immunoglobulin M
IGR: Intergenic region
I𝜅B: Inhibitors of NF-𝜅B
IL: Interleukin (IL6, IL8, IL10, IL12)
IM: Inner membrane
IS: Insertion sequence (IS1016, IS1106-like,
IS1301, IS1655)
katA: Catalase A
LAMP1: Lysosomal-associated membrane protein 1
lbp: Lactoferrin-binding protein
lct: Lactate permease
LGT: Lateral Gene Transfer
lgt: Prolipoprotein diacylglyceryl transferase
(lgtA, lgtB, lgtC, lgtD, lgtE, lgtG)
L-NNT: Lacto-N-neotetraose
LOS: Lipooligosaccharides
LPS: Lipopolysaccharides
MAC: Membrane attack complex
MAPK: Mitogen-activated protein kinase
MAPKK: Mitogen-activated protein kinase Kinase
MATS: Meningococcal Antigen Typing System
MDA: Meningococcal disease-associated island
MHC: Major histocompatibility complex
MIP: Macrophage infectivity potentiator
MMEs: Minimal mobile elements
mltA: Membrane-boundlytic transglycosylase A
mo: Month
mRNA: messenger RNA
msf : Meningococcal surface fibril
msr: Methionine sulfoxide reductase
MS: Mass spectrometry
mspA: Meningococcal serine protease A
mtr: Multiple transferable resistance
MWNTs: Multiwalled carbon nanotubes
N.: Neisseria (N. lactamica, N. sicca, N. elon-
gata, N. cinerea, and N. flavescens)
nadA: Neisserial adhesin A
NCAM-1: Neural cell adhesion molecule 1
NEMIS: Neisseriaminiature insertion sequences
NETs: Neutrophil extracellular traps
NF-𝜅B: Nuclear factor kappa-light-chain-enhancer
of activated B cells
N. gonorrheae: Neisseria gonorrheae
NHBA: Neisserial heparin binding antigen
nhhA: Neisseria hia/hsf homologue
NIMEs: Neisserial intergenic mosaic elements
NKs: Natural killer cells
NLRs: NOD-like receptors
N. meningitidis: Neisseria meningitidis
NO: Nitric oxide
NOD: Nucleotide-binding Oligomerization
Domain
NTPase: Nucleoside triphosphatases
oat: O-acetyltransferase
OM: Outer membrane
OMPs: Outer membrane proteins
OMVs: Outer membrane vesicles
OMPLA: Outermembrane phospholipase A
Opa: Opacity-associated protein a
Opc: Opacity-associated protein c
ORF: Open reading frame
pac: Peptidoglycan O-acyltransferase
PAI: Pathogenic island
PAMPs: Pathogen-associated molecular patterns
pil: Pilin (pilC: OM/cell surface pilin; pilD:
prepilin-processing leader peptidase; pilF:
traffic NTPase; pilG: pilus assembly pro-
tein; pilM: biogenesis protein; pilP: pilot
protein; pilQ: secretin; pilT: traffic NTPase;
pilW: pilus stabilization protein)
PN: Peroxynitrite
por: Porin
pptA: Pilin phosphorylcholine transferase A
PRRs: Pattern recognition receptors
PTK: Protein tyrosine kinase
RANTES: Regulated on activation, normal T cell
expressed and secreted
RecA: Recombinase A
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REP2: Repetitive extragenic palindromic
sequence
RIG-I: Retinoic acid-inducible gene 1
rLP2086: Recombinant lipoprotein 2086
RLRs: RIG-1-like receptors
RNA: Ribonucleic acid
RNS: Reactive nitrogen species
ROS: Reactive oxygen species
sia: Polysialic acid capsule biosynthesis protein
(siaA, siaB, siaC, siaD)
SMAD: Small Mothers Against Decapentaplegic
sod: Superoxide dismutase (sodB, sodC)
SOMVs: Spontaneously released OMVs
SSM: Slipped strand mispairing
SSR: Simple Sequence Repeat
tbp: Transferrin-binding protein
TGF: Transforming Growth Factor
Th: T-cell helper
TI: T-cell Independent
TLR: Toll-like receptor (TLR2, TLR4, TLR5,
TLR9)
TNF: Tumor Necrosis Factor
tspA: T cell stimulating protein A
UK: United Kingdom
USA: United States of America
UTR: Untranslated Region
w: Week
WGS: Whole-genome sequencing
WNT: Wingless-related integration site
y: Year
znuD: Zinc uptake component D.
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